Cation Exchange Resin Achieves Higher Dynamic Binding Capacity
Tosoh Bioscience adds TOYOPEARL Sulfate-650F, a strong cation exchange resin that exhibits high salt tolerance, to its process media product line.
Tosoh Bioscience, a provider of chromatographic resins for the purification of biopharmaceutical drugs in commercial manufacturing processes, introduced TOYOPEARL Sulfate-650F, a strong cation exchange resin that exhibits a high salt tolerance, for sale in the Americas. TOYOPEARL Sulfate-650F resin allows for lowered operating costs by offering higher dynamic binding capacities for IgG. This resin can achieve a dynamic binding capacity of >120 g/L of monoclonal antibody (mAb) and exhibits pressure-flow properties at 30 cm inner diameter of up to 500 cm/hr (0.2 MPa). The resin is ideal for applications performed in physiological conditions or for post-protein A removal of aggregates. According to the company, the chromatographic resin captures mAb aggregates over a wide pH range without losing its binding capacity for mAb, resulting in higher resolution between monomer and aggregates.
Source: Tosoh Bioscience
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Shilpa Medicare Launches ‘Hybrid CDMO’ at DCAT Week 2025
March 17th 2025This model is being positioned by Shilpa as a dual approach that offers comprehensive discovery, clinical, and commercial outsourcing services in addition to commercially ready, “off-the-shelf” novel formulations for b2b licensing.
